Δ9-Tetrahydrocannabinol inhibits cell cycle progression by downregulation of E2F1 in human glioblastoma multiforme cells

Acta Oncologica

Volumn 47, Issue 6, 2008, Pages 1062-1070

  Galanti, Gil ^a,b   Fisher, Tamar ^b   Kventsel, Iris ^b   Shoham, Jacob ^a   Gallily, Ruth ^c   Mechoulam, Raphael ^c   Lavie, Gad ^b   Amariglio, Ninette ^b   Rechavi, Gideon ^b   Toren, Amos ^b  

^a BAR ILAN UNIVERSITY   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; CYCLIN A; DRONABINOL; THYMIDYLATE SYNTHASE; TRANSCRIPTION FACTOR E2F1;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE PROGRESSION; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG INHIBITION; GLIOBLASTOMA; HUMAN; HUMAN CELL; MEDIATOR; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RNA TRANSCRIPTION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL CYCLE; CELL DIVISION; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DOWN-REGULATION; E2F1 TRANSCRIPTION FACTOR; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TETRAHYDROCANNABINOL; THYMIDYLATE SYNTHASE; TIME FACTORS; UP-REGULATION;

EID: 51449092478     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860701678787     Document Type: Article

References (25)

1. Collins VP. Gliomas. Cancer Surv 1998;32:37-51.
2. Kraemer DF, Fortin D, Neuwelt EA. Chemotherapeutic dose intensification for treatment of malignant brain tumors: Recent developments and futures directions. Curr Neurol Neurosci 2002;2:216-24.
3. Smith JS, Tachibana I, Passe SM, Huntley BK, Borell TJ, Iturria N, et al. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and Glioblastoma Multiform. J Natl Cancer Inst 2001;15;93:1246-56.
4. Kleihues P, Ohgaki H. Primary and secondary glioblastomas: From concept to clinical diagnosis. Neurooncol 1999;1:44-51.
5. Porter AC, Felder CC. The endocannabinoid nervous system: Unique opportunities for therapeutic intervention. Pharmacol Ther 2001;90:45-60.
6. Munson AE, Harris LS, Friedman MA, Dewey WL, Carchman RA. Antineoplastic activity of cannabinoids. J Natl Cancer Inst 1975;55:597-602.
7. Galve-Roperh I, Sánchez C, Cortés ML, del Pulgar TG, Izquierdo M, Guzmán M. Anti-tumoral action of cannabinoids: Involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat Med 2000;6:313-9.
8. Bifulco M, Laezza C, Portella G, Vitale M, Orlando P, De Petrocellis L, et al. Control by the endogenous cannabinoid system of ras oncogene-dependent tumor growth. FASEB J 2001;15:2745-7.
9. Guzmán M, Sánchez C, Galve-Roperh I. Control of the cell survival/death decision by cannabinoids. J Mol Med 2001;78:613-25.
10. Caffarel MM, Sarrio D, Palacios J, Guzman M, Sanchez C. Delta9 tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation. Cancer Res 2006;1;66(13):6615-21.
11. Grana X, Reddy EP. Cell cycle control in mammalian cells: Role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene 1995;11:211-9.
12. Morgan DO. Principles of CDK regulation. Nature 1995; 374:131-4.
13. Pagano M, Pepperkok R, Verde F, Ansorge W, Draetta G. Cyclin A is required at two points in the human cell cycle. EMBO J 1992;11:961-71.
14. Arap W, Nishikawa R, Furnari FB, Cavenee WK, Huang H-SS. Replacement of the p16/CDKN2 gene suppresses human Glioma cell growth. Cancer Res 1995;55:1351-4.
15. DeGregori J, Kowalik T, Nevins JR. Cellular targets for activation by the E2F1 transcription factor include DNA synthesis- and G1/S-regulatory genes. Mol Cell Biol 1995;15:4215-24.
16. Dyson N. The regulation of E2F by pRB-family proteins. Genes Dev 1998;12:2245-62.
17. Mizutani Y, Wada H, Yoshida O, Fukushima M, Nonomura M, Nasao M, et al. Significance of thymidylate synthase activity in renal cell carcinoma. Clin Cancer Res 2003;9:1453-60.
18. Nomura T, Nakagawa M, Fujita Y, Hanada T, Mimata H, Nomura Y. Clinical signification of thymidylate synthase expression in bladder cancer. Int J Urol 2002;9:368-76.
19. Shintani Y, Ohta M, Hirabayashi H, Tanaka H, Iuchi K, Nakagawa K, et al. New prognostic indicator for non-small-cell lung cancer, quantitation of thymidylate synthase by real-time reverse transcription polymerase chain reaction. Int J Cancer 2003;104:790-5.
20. Schmidt EE, Ichimura K, Reifenberger G, Collins VP. CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res 1994;54:6321-4.
21. Kyritsis AP, Zhang B, Zhang W, Xiao M, Takeshima H, Bondy ML, et al. Mutations of the p16 gene in gliomas. Oncogene 1996;12:63-7.
22. Costello JF, Berger MS, Huang H-JS, Cavenee WK. Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation. Cancer Res 1996;56:2405-10.
23. Chintala SK, Fueyo J, Gomez-Manzano C, Venkaiah B, Bjerkvig R, Yung WKA, et al. Adenovirus-mediated p16/CDKN2 gene transfer suppress Glioma invasion in vitro. Oncogene 1997;15:2049-57.
24. 1- and S phase regulators. J Cell Physiol 2001;187:1-10.
25. Campanero MR, Flemington EK. Regulation of E2F through ubiquitin-proteasome-dependent degradation: Stabilization by the pRB tumor suppressor protein. Proc Natl Acad Sci USA 1997;94:2221-6.